The consistent therapeutic benefits observed with diverse Hsp90 inhibitors, such as Geldanamycin, Ganetespib, 17-AAG, and RGRN - 305, administered systemically or topically, provide strong rationale for further clinical evaluation in patients with AD (Table 1). Here, HSP90AA1 is linked to Alzheimer disease.